Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmune Bio Inc (NQ: INMB )

4.760 +0.200 (+4.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 186,960
Open 4.560
Bid (Size) 4.380 (9)
Ask (Size) 7.020 (1)
Prev. Close 4.560
Today's Range 4.470 - 4.860
52wk Range 4.450 - 14.74
Shares Outstanding 17,703,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
From INmune Bio, Inc.
Via GlobeNewswire

Performance

YTD
-57.58%
-57.58%
1 Month
-7.39%
-7.39%
3 Month
-26.20%
-26.20%
6 Month
-52.96%
-52.96%
1 Year
-44.91%
-44.91%

More News

Read More
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces $13.0 Million Registered Direct Offering
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
From INmune Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
INmune Bio Inc. to Join Russell 3000® Index
From INmune Bio, Inc.
Via GlobeNewswire
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
From INmune Bio, Inc.
Via GlobeNewswire
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.